Fluidx says ULTRA embolic gel showed continued clinical success in New Zealand case

Fluidx Medical Technology said its ULTRA embolic device was used to treat a large renal cell carcinoma tumor at Auckland City Hospital in New Zealand. The company says the ready-to-use gel is designed to improve control during embolization and may simplify treatment of hypervascular tumors and bleeding vessels.

Why it matters: - Fluidx Medical Technology is positioning ULTRA as a simpler embolic option for physicians treating tumors and bleeding in the peripheral vasculature. - The company says the device is designed to reduce preparation steps and improve control during embolization, which could matter in complex cases where time and precision are critical. - The broader embolic market exceeds $3.5 billion a year, underscoring the commercial stakes for devices that are easier to use.

What happened: - Fluidx Medical Technology said ULTRA was most recently used at Auckland City Hospital in Auckland, New Zealand, to treat a large, right-sided renal cell carcinoma tumor. - Brendan Buckley, M.D., an investigator at Auckland City Hospital, said the ready-to-use syringe format helps when additional embolization is needed mid-procedure. - Buckley also said the syringe provides haptic feedback that allows precise control, especially in complex arterial territories.

The details: - ULTRA is designed for embolization of hypervascular tumors and blood vessels to control bleeding in the peripheral vasculature. - The device does not require preparation before use. - Fluidx said the embolic gel can be delivered using any catheter. - The company said the gel was delivered into a range of vessel sizes and achieved consistent filling in the Auckland case. - Fluidx said its embolic gels were designed around versatility, simplicity and broad deliverability. - The company's current pipeline includes GPX, ULTRA and IMPASS embolic technologies for peripheral vascular, interventional oncology and neurovascular embolization. - Fluidx said its portfolio does not use toxic dimethyl sulfoxide or other precursors, does not glue catheters into the body, does not require special delivery systems and does not need special mixers or preparation stations. - The company said GPX, ULTRA and IMPASS are under development and are for research, educational and engineering use only. - Fluidx said the products do not have marketing clearance or approval in any market.

Between the lines: - The New Zealand case gives Fluidx another clinical example to point to as it tries to validate ULTRA's performance and safety. - The emphasis on no-prep use and catheter flexibility suggests the company is targeting workflow pain points as much as clinical outcomes. - The market pitch is less about a single new treatment category and more about making embolization more predictable and easier to deliver across vessel sizes.

What's next: - Fluidx is likely to keep using individual clinical cases to build evidence around the ULTRA platform. - The company also appears to be advancing a broader embolic pipeline spanning peripheral vascular, oncology and neurovascular uses. - Any wider clinical or commercial rollout will depend on future development and regulatory clearance.

The bottom line: - Fluidx is trying to prove that a ready-to-use embolic gel can make embolization simpler, more controllable and more consistent for physicians.